

| Catalog No. | HB615021 |
|---|---|
| Description |
Recombinant Human CD59 Protein, C-Fc (HB615021) expressed in Mammalian Cells, spanning Met1-Glu101. Purity: >90% by SDS-PAGE.
Highlights
|
| Expression system | Mammalian cells |
| Accession | P13987 |
| Protein length | Met1-Glu101 |
| Applications | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| Species | Homo sapiens (Human) |
| Nature | Recombinant |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >90% as determined by SDS-PAGE. |
| Predicted molecular weight | 37.77 kDa |
| Form | Lyophilized |
| Storage buffer | Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Reconstitution | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| Shipping | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | 1F5 antigen, 20 kDa homologous restriction factor, CD59, CD59 glycoprotein, HRF-20, HRF20, MAC-IP, MAC-inhibitory protein, MACIF, MEM43 antigen, MIC11, MIN1, MIN2, MIN3, MIRL, MSK21, Membrane attack complex inhibition factor, Membrane inhibitor of reactive lysis, Protectin |
| Background | CD59 glycoprotein is a ~14 kDa protein. Potent inhibitor of the complement membrane attack complex (MAC) action, which protects human cells from damage during complement activation. Acts by binding to the beta-haipins of C8 (C8A and C8B) components of the assembling MAC, forming an intermolecular beta-sheet that prevents incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. 1. Farkas, I. et al. (2002) The Journal of physiology 539, 537-45. PMID: 11882685 2. Meri, S. et al. (1990) Immunology 71, 1-9. PMID: 1698710 3. Okada, H. et al. (1989) Biochemical and biophysical research communications 162, 1553-9. PMID: 2475111 4. Davies, A. et al. (1989) The Journal of experimental medicine 170, 637-54. PMID: 2475570 5. Sugita, Y. et al. (1989) Journal of biochemistry 106, 555-7. PMID: 2606909 6. Bodian, DL. et al. (1997) The Journal of experimental medicine 185, 507-16. PMID: 9053451 7. Couves, EC. et al. (2023) Nature communications 14, 890. PMID: 36797260 |
| Note | For research use only |




Contact us for custom quotes, bulk requests and any other issues.
Mail: [email protected]
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский